Scarica l'app Stockscreener
300.16
0.82%
-2.48
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MDGL Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$302.64
Aprire:
$300.01
Volume 24 ore:
217.85K
Relative Volume:
0.69
Capitalizzazione di mercato:
$6.27B
Reddito:
-
Utile/perdita netta:
$-518.67M
Rapporto P/E:
-11.95
EPS:
-25.12
Flusso di cassa netto:
$-438.32M
1 W Prestazione:
+5.33%
1M Prestazione:
+9.05%
6M Prestazione:
-2.73%
1 anno Prestazione:
+7.46%
Intervallo 1D:
$291.45
$301.39
Intervallo di 1 settimana:
$277.64
$314.22
Portata 52W:
$200.63
$377.46
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Nome
Madrigal Pharmaceuticals Inc
Settore
Industria
Telefono
404-380-9263
Indirizzo
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Confronta MDGL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
300.16 | 6.27B | 0 | -518.67M | -438.32M | -25.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-28 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | Reiterato | H.C. Wainwright | Buy |
| 2024-06-28 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-06-11 | Iniziato | Wolfe Research | Outperform |
| 2024-04-22 | Iniziato | BofA Securities | Underperform |
| 2024-03-15 | Aggiornamento | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | Iniziato | Citigroup | Buy |
| 2024-02-26 | Downgrade | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | Reiterato | Oppenheimer | Outperform |
| 2022-12-19 | Reiterato | H.C. Wainwright | Buy |
| 2022-12-19 | Reiterato | Piper Sandler | Overweight |
| 2022-12-19 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-08-06 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | Ripresa | Goldman | Buy |
| 2020-11-24 | Ripresa | Evercore ISI | Outperform |
| 2020-11-06 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-06-05 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-05-05 | Iniziato | Chardan Capital Markets | Buy |
| 2020-01-30 | Iniziato | Canaccord Genuity | Buy |
| 2020-01-09 | Aggiornamento | UBS | Neutral → Buy |
| 2019-11-07 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-25 | Iniziato | Stifel | Hold |
| 2019-06-10 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-22 | Iniziato | SVB Leerink | Outperform |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-12-12 | Iniziato | B. Riley FBR | Neutral |
| 2018-11-19 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-09-04 | Iniziato | Citigroup | Buy |
| 2018-08-06 | Downgrade | Goldman | Buy → Neutral |
| 2018-06-28 | Iniziato | Raymond James | Mkt Perform |
Mostra tutto
Madrigal Pharmaceuticals Inc Borsa (MDGL) Ultime notizie
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
EU Decision Time For Madrigal’s MASH Drug Resmetirom And 11 Others - insights.citeline.com
(MDGL) Investment Analysis - news.stocktradersdaily.com
Madrigal Pharmaceuticals to Present at 46th Annual Goldman Sachs Health Care Conference - MSN
Transcript : Madrigal Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 10 - MarketScreener
Cantor Fitzgerald Predicts MDGL FY2026 Earnings - Defense World
Head-To-Head Survey: Larimar Therapeutics (NASDAQ:LRMR) vs. Madrigal Pharmaceuticals (NASDAQ:MDGL) - Defense World
Reviewing Sonnet BioTherapeutics (NASDAQ:SONN) and Madrigal Pharmaceuticals (NASDAQ:MDGL) - Defense World
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
(MDGL) On The My Stocks Page - news.stocktradersdaily.com
Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference - GlobeNewswire
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stake Lowered by Ameriprise Financial Inc. - Defense World
Roivant Staying ‘Patient’ On Deals, Leaving Investors Waiting - insights.citeline.com
Madrigal Pharmaceuticals’ SWOT analysis: rezdiffra’s promise drives stock outlook - Investing.com
Madrigal Pharmaceuticals’ SWOT analysis: rezdiffra’s promise drives stock outlook By Investing.com - Investing.com UK
Cetera Investment Advisers Has $889,000 Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) - Defense World
When (MDGL) Moves Investors should Listen - news.stocktradersdaily.com
In Search Of Tailwind, Sailing Doldrums With Madrigal Pharmaceuticals Stock (MDGL) - Seeking Alpha
A Short History Of MASH Deals, Culminating In GSK/Boston Pharma - insights.citeline.com
Will Other Major MASH Deals Follow GSK/Boston Pharma? - insights.citeline.com
2 Monster Stocks in the Making to Buy Now and Hold for 10 Years - AOL.com
Transcript : Madrigal Pharmaceuticals, Inc.Special Call - marketscreener.com
Where are the Opportunities in (MDGL) - news.stocktradersdaily.com
Madrigal Pharmaceuticals Reports Promising Two-Year Data for Rezdiffra in MASH Cirrhosis - MSN
Madrigal Pharma Short Interest Reaches 4-Month High: Retail Investors Still Bullish On Stock - MSN
MDGL Stock Gains on Positive Phase 3 Trial Results for Rezdiffra - GuruFocus
MDGL Stock Gains on Positive Phase 3 Trial Results for Rezdiffra | MDGL Stock News - GuruFocus
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis - The Manila Times
Madrigal Says New Clinical Data Demonstrating Rezdiffra Significantly Improved Multiple Noninvasive Tests & Portal Hypertension Risk In Patients With Compensated Mash Cirrhosis - marketscreener.com
Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis - GlobeNewswire Inc.
Madrigal Pharmaceuticals, Inc. (MDGL): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside Potential - Yahoo Finance
Billionaire Nicholas J. Pritzker’s 8 Stocks with Huge Upside Potential - Insider Monkey
Madrigal Pharmaceuticals (MDGL): Among Billionaire John Paulson’s Stocks with Huge Upside Potential - Insider Monkey
Madrigal Pharmaceuticals: An Encouraging Start For Rezdiffra (NASDAQ:MDGL) - Seeking Alpha
Billionaire John Paulson’s 10 Stocks with Huge Upside Potential - Insider Monkey
What is B. Riley’s Estimate for MDGL FY2028 Earnings? - Defense World
Earnings Beat: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2025 Earnings Call Transcript - Insider Monkey
Decoding Madrigal Pharmaceuticals Inc (MDGL): A Strategic SWOT I - GuruFocus
(MDGL) Trading Signals - news.stocktradersdaily.com
Madrigal Pharmaceuticals (MDGL): UBS Maintains Buy Rating, Raise - GuruFocus
Madrigal Pharmaceuticals (MDGL): UBS Maintains Buy Rating, Raises Price Target | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals (MDGL) Target Price Raised by Canaccord - GuruFocus
Madrigal Pharmaceuticals (MDGL) Receives a Price Target Boost fr - GuruFocus
Madrigal Pharmaceuticals (MDGL) Receives a Price Target Boost from B. Riley Securities | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals (MDGL) Sees Price Target Boost on Stron - GuruFocus
UBS Increases Price Target for Madrigal Pharmaceuticals (MDGL) | - GuruFocus
UBS Increases Price Target for Madrigal Pharmaceuticals (MDGL) | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals (MDGL) Sees Price Target Boost on Strong Sales | MDGL Stock News - GuruFocus
Madrigal Pharmaceuticals to Present Breakthrough Resmetirom Data at EASL Congress 2025 - MSN
Madrigal Pharmaceuticals Inc Azioni (MDGL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Madrigal Pharmaceuticals Inc Azioni (MDGL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| CRAVES FRED B | Director |
Mar 13 '25 |
Option Exercise |
65.06 |
7,742 |
503,695 |
357,818 |
| CRAVES FRED B | Director |
Mar 12 '25 |
Sale |
331.84 |
7,728 |
2,564,426 |
350,076 |
| CRAVES FRED B | Director |
Mar 13 '25 |
Sale |
325.25 |
7,742 |
2,518,053 |
350,076 |
0.39%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):